{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T05:48:59Z","timestamp":1793166539780,"version":"4.5.0"},"reference-count":103,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T00:00:00Z","timestamp":1760400000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"publisher","award":["INV-038215"],"award-info":[{"award-number":["INV-038215"]}],"id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Incomplete tuberculosis (TB) treatment adherence may lead to unsuccessful treatment and relapse. Digital adherence technologies (DATs) may allow more person-centric approaches for supporting treatment adherence. We conducted a systematic review (PROSPERO- CRD42022313166) to evaluate the impact of DATs on adherence, treatment outcomes and patient-reported outcomes in persons treated for TB.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We searched MEDLINE, Embase, CENTRAL, CINAHL, Web of Science and preprints from Europe PMC, and clinicaltrials.gov for relevant literature from January 2000 to March 2024. We considered experimental or cohort studies reporting quantitative comparisons of adherence, treatment outcomes and patient-reported outcomes between a DAT and the standard of care in each setting. We excluded studies where the technology was used only to log visit attendance or for \u201croutine telephone calls\u201d to patients. Risk of bias was assessed using the Cochrane risk of bias assessment tool and the Newcastle- Ottawa Scale. Pre-specified subgroup analyses considered study design, specific DAT interventions as well as income levels in the countries where studies were conducted.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-six studies (total 86,586 participants) were included evaluating SMS-based interventions (k\u2009=\u200918 studies), feature phone-based interventions (k\u2009=\u20098), medication sleeves with phone calls (branded as \u201c99DOTS,\u201d k\u2009=\u20096), video-observed therapy (VOT; k\u2009=\u200918), smartphone apps (k\u2009=\u20097), digital pillboxes (k\u2009=\u200921), ingestible sensors (k\u2009=\u20091), and interventions combining two DATs (k\u2009=\u20092).<\/jats:p>\n                    <jats:p>\n                      Overall, the use of DATs was associated with a modest increase in treatment success in TB disease in both RCTs (OR\u2009=\u20091.14 [0.99, 1.30]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200957%, k\u2009=\u200934, very low certainty evidence) and observational studies (OR\u2009=\u20091.11 [0.94, 1.30]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200974%, k\u2009=\u200922, very low certainty evidence). Additionally, DAT use was linked to a significant increase in reporting of adverse events in RCTs (OR\u2009=\u20091.57 [1.25, 1.97]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200912%, k\u2009=\u20096, moderate certainty) while observational studies showed a similar but non-significant finding (OR\u2009=\u20091.39 [0.93, 2.09]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%, k\u2009=\u20093, moderate certainty). VOT was associated with an increased likelihood of treatment completion in TB infection (OR 4.69 [2.08; 10.55]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%, k\u2009=\u20092, low certainty evidence). VOT also increased frequency of adverse event reporting, as demonstrated in RCTs (OR\u2009=\u20091.9 [1.27; 2.84]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%, k\u2009=\u20093, moderate certainty evidence) and a similar but non-significant effect in observational studies (OR\u2009=\u20091.48 [0.91; 2.42]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u20090%, k\u2009=\u20092, low certainty evidence). Other interventions involving smartphone apps were associated with increased treatment success in TB disease, with a significant effect observed in RCTs (OR 2.17 [1.07; 4.4]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200920%, k\u2009=\u20093, low certainty evidence) and a non-significant effect in observational studies (OR 1.51 [0.53; 4.3]; I\n                      <jats:sup>2<\/jats:sup>\n                      \u2009=\u200960%, k\u2009=\u20093, very low certainty evidence). In contrast, interventions with 99DOTS were not associated with improvements in short-term clinical outcomes. There was substantial methodological heterogeneity among studies reporting on adherence. Few studies assessed patient-reported outcomes, though satisfaction was generally higher with DATs.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Some DATs, notably VOT and smartphone apps, have been successfully used to support TB treatment. Although in many cases DATs did not improve clinical outcomes, they may improve efficiency and adherence, and may be preferred to traditional directly observed therapy by persons with TB. However, evidence remains highly variable, and generalizability limited. Higher quality data are needed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>PROSPERO- CRD42022313166<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11503-3","type":"journal-article","created":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T15:30:53Z","timestamp":1760455853000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["The impact of digital adherence technologies on treatment outcomes, adherence, and patient-reported outcomes in tuberculosis: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"25","author":[{"given":"Mona S.","family":"Mohamed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miranda","family":"Zary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cedric","family":"Kafie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chimweta I.","family":"Chilala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shruti","family":"Bahukudumbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Foster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genevieve","family":"Gore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Fielding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramnath","family":"Subbaraman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Schwartzman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,14]]},"reference":[{"key":"11503_CR1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002152","author":"RMGJ Houben","year":"2016","unstructured":"Houben RMGJ, Dodd PJ. The global burden of latent tuberculosis infection: a re-estimation using mathematical modelling. PLoS Med. 2016. https:\/\/doi.org\/10.1371\/journal.pmed.1002152.","journal-title":"PLoS Med"},{"key":"11503_CR2","unstructured":"World Health Organization Global Tuberculosis Report 2024. 2024 [cited 30 July 2025]. Available: https:\/\/iris.who.int\/bitstream\/handle\/10665\/379339\/9789240101531-eng.pdf?sequence=1"},{"key":"11503_CR3","unstructured":"World Health Organization. Global Tuberculosis Control - Surveillance, Planning, Financing, 2004\u202f: WHO report 2004. World Health Organization; 2004."},{"key":"11503_CR4","unstructured":"World Health Organization. Handbook for the use of digital technologies to support tuberculosis medication adherence. 2017 [cited 5 Mar 2024]. Available: http:\/\/apps.who.int\/bookorders."},{"key":"11503_CR5","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1136\/bmjgh-2018-001018","volume":"3","author":"R Subbaraman","year":"2018","unstructured":"Subbaraman R, De Mondesert L, Musiimenta A, Pai M, Mayer KH, Thomas BE, et al. Digital adherence technologies for the management of tuberculosis therapy: mapping the landscape and research priorities Analysis. BMJ Glob Health. 2018;3:1018. https:\/\/doi.org\/10.1136\/bmjgh-2018-001018.","journal-title":"BMJ Glob Health"},{"key":"11503_CR6","doi-asserted-by":"publisher","DOI":"10.2196\/33062","author":"A Ridho","year":"2022","unstructured":"Ridho A, Alfian SD, van Boven JFM, Levita J, Yalcin EA, Le L, et al. Digital health technologies to improve medication adherence and treatment outcomes in patients with tuberculosis: systematic review of randomized controlled trials. J Med Internet Res. 2022. https:\/\/doi.org\/10.2196\/33062.","journal-title":"J Med Internet Res"},{"key":"11503_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/J.IJMEDINF.2022.104687","volume":"159","author":"YJ Wong","year":"2022","unstructured":"Wong YJ, Ng KY, Lee SWH. Digital health use in latent tuberculosis infection care: a systematic review. Int J Med Inform. 2022;159: 104687. https:\/\/doi.org\/10.1016\/J.IJMEDINF.2022.104687.","journal-title":"Int J Med Inform"},{"key":"11503_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002595","author":"N Alipanah","year":"2018","unstructured":"Alipanah N, Jarlsberg L, Miller C, Linh NN, Falzon D, Jaramillo E, et al. Adherence interventions and outcomes of tuberculosis treatment: a systematic review and meta-analysis of trials and observational studies. PLoS Med. 2018. https:\/\/doi.org\/10.1371\/journal.pmed.1002595.","journal-title":"PLoS Med"},{"key":"11503_CR9","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1056\/nejmc1806550","volume":"381","author":"E Yoeli","year":"2019","unstructured":"Yoeli E, Rathauser J, Bhanot SP, Kimenye MK, Mailu E, Masini E, et al. Digital health support in treatment for tuberculosis. N Engl J Med. 2019;381:986\u20137. https:\/\/doi.org\/10.1056\/nejmc1806550.","journal-title":"N Engl J Med"},{"key":"11503_CR10","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1002891","author":"SH Browne","year":"2019","unstructured":"Browne SH, Umlauf A, Tucker AJ, Low J, Moser K, Garcia JG, et al. Wirelessly observed therapy compared to directly observed therapy to confirm and support tuberculosis treatment adherence: a randomized controlled trial. PLoS Med. 2019. https:\/\/doi.org\/10.1371\/journal.pmed.1002891.","journal-title":"PLoS Med"},{"key":"11503_CR11","doi-asserted-by":"publisher","unstructured":"Sodhi R, Vatsyayan V, Panibatla V, Sayyad K, Williams J, Pattery T, et al. Impact of a pilot mHealth intervention on treatment outcomes of TB patients seeking care in the private sector using Propensity Scores Matching \u2013 Evidence collated from New Delhi, India. medRxiv. 2023; 2023.12.05.23299517. https:\/\/doi.org\/10.1101\/2023.12.05.23299517","DOI":"10.1101\/2023.12.05.23299517"},{"key":"11503_CR12","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1002\/wmh3.337","volume":"12","author":"D Das Gupta","year":"2020","unstructured":"Das Gupta D, Patel A, Saxena D, Koizumi N, Trivedi P, Patel K, et al. Choice-based reminder cues: findings from an mHealth study to improve Tuberculosis (TB) treatment adherence among the urban poor in India. World Med Health Policy. 2020;12:163\u201381. https:\/\/doi.org\/10.1002\/wmh3.337.","journal-title":"World Med Health Policy"},{"key":"11503_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.lana.2022.100291","volume":"13","author":"SJ Iribarren","year":"2022","unstructured":"Iribarren SJ, Milligan H, Chirico C, Goodwin K, Schnall R, Telles H, et al. Patient-centered mobile tuberculosis treatment support tools (TB-TSTs) to improve treatment adherence: A pilot randomized controlled trial exploring feasibility, acceptability and refinement needs. Lancet Regional Health Am. 2022;13: 100291. https:\/\/doi.org\/10.1016\/j.lana.2022.100291.","journal-title":"Lancet Regional Health Am"},{"key":"11503_CR14","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01596-2017","author":"BK Ngwatu","year":"2018","unstructured":"Ngwatu BK, Nsengiyumva NP, Oxlade O, Mappin-Kasirer B, Nguyen NL, Jaramillo E, et al. The impact of digital health technologies on tuberculosis treatment: a systematic review. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.01596-2017.","journal-title":"Eur Respir J"},{"key":"11503_CR15","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1016\/S0140-6736(10)61997-6","volume":"376","author":"RT Lester","year":"2010","unstructured":"Lester RT, Ritvo P, Mills EJ, Kariri A, Karanja S, Chung MH, et al. Effects of a mobile phone short message service on antiretroviral treatment adherence in Kenya (WelTel Kenya1): a randomised trial. Lancet. 2010;376:1838\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(10)61997-6.","journal-title":"Lancet"},{"key":"11503_CR16","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1016\/J.AMEPRE.2021.10.013","volume":"62","author":"CB Truong","year":"2022","unstructured":"Truong CB, Tanni KA, Qian J. Video-observed therapy versus directly observed therapy in patients with tuberculosis. Am J Prev Med. 2022;62:450\u20138. https:\/\/doi.org\/10.1016\/J.AMEPRE.2021.10.013.","journal-title":"Am J Prev Med"},{"key":"11503_CR17","doi-asserted-by":"publisher","DOI":"10.1186\/S12879-020-4765-X","author":"KD Gashu","year":"2020","unstructured":"Gashu KD, Gelaye KA, Mekonnen ZA, Lester R, Tilahun B. Does phone messaging improves tuberculosis treatment success? A systematic review and meta-analysis. BMC Infect Dis. 2020. https:\/\/doi.org\/10.1186\/S12879-020-4765-X.","journal-title":"BMC Infect Dis"},{"key":"11503_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PMED.1003583","volume":"18","author":"MJ Page","year":"2021","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18: e1003583. https:\/\/doi.org\/10.1371\/JOURNAL.PMED.1003583.","journal-title":"PLoS Med"},{"key":"11503_CR19","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177\u201388. https:\/\/doi.org\/10.1016\/0197-2456(86)90046-2.","journal-title":"Control Clin Trials"},{"key":"11503_CR20","doi-asserted-by":"crossref","unstructured":"Viechtbauer W. Conducting Meta-Analyses in R with the metafor Package. JSS Journal of Statistical Software. 2010. Available: http:\/\/www.jstatsoft.org\/","DOI":"10.18637\/jss.v036.i03"},{"key":"11503_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1136\/ebmental-2019-300117","volume":"22","author":"S Balduzzi","year":"2019","unstructured":"Balduzzi S, R\u00fccker G, Schwarzer G. How to perform a meta-analysis with R: a practical tutorial. Evid Based Ment Health. 2019;22:153\u201360. https:\/\/doi.org\/10.1136\/ebmental-2019-300117.","journal-title":"Evid Based Ment Health"},{"key":"11503_CR22","unstructured":"New World Bank country classifications by income level: 2022\u20132023. [cited 12 Nov 2023]. Available: https:\/\/blogs.worldbank.org\/opendata\/new-world-bank-country-classifications-income-level-2022-2023"},{"key":"11503_CR23","doi-asserted-by":"crossref","unstructured":"Egger M, Smith GD, Schneider M, Minder C. Papers Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997.","DOI":"10.1136\/bmj.315.7109.629"},{"issue":"1","key":"11503_CR24","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1037\/0033-2909.117.1.167","volume":"117","author":"V Hasselblad","year":"1995","unstructured":"Hasselblad V, Hedges LV. Meta-analysis of screening and diagnostic tests. Psychol Bull. 1995;117(1):167\u201378. https:\/\/doi.org\/10.1037\/0033-2909.117.1.167.","journal-title":"Psychol Bull"},{"key":"11503_CR25","unstructured":"Jerene D, Van Kalmthout K, Levy J, Alacapa J, Deyanova N, Dube T, et al. Effectiveness of digital adherence technologies in improving treatment outcomes in persons with drug-susceptible tuberculosis: results from pragmatic, cluster randomized trials in four countries. Available: https:\/\/ssrn.com\/abstract=4720744"},{"key":"11503_CR26","unstructured":"Siddiqui S, Dana Wiltz-Beckham ;, Fields K, Haynie A, Reed BC, Les Becker ;, et al. Video Directly Observed Therapy for Tuberculosis Treatment at Harris County Public Health: A Cost Analysis and Adherence Assessment. TPHA Journal. 2019."},{"key":"11503_CR27","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1001876","author":"X Liu","year":"2015","unstructured":"Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, et al. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med. 2015. https:\/\/doi.org\/10.1371\/journal.pmed.1001876.","journal-title":"PLoS Med"},{"key":"11503_CR28","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1089\/tmj.2023.0084","volume":"30","author":"X Wang","year":"2024","unstructured":"Wang X, Fu Q, Zhou M, Li Y. How integrated digital tools can improve Tuberculosis medication adherence: a longitudinal study in China. Telemedicine and e-Health. 2024;30:490\u20138. https:\/\/doi.org\/10.1089\/tmj.2023.0084.","journal-title":"Telemedicine and e-Health"},{"key":"11503_CR29","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2023.923319","author":"Z Wu","year":"2023","unstructured":"Wu Z, Lu L, Li Y, Chen J, Zhang Z, Ning C, et al. Effect of mobile health reminders on tuberculosis treatment outcomes in Shanghai, China: a prospective cohort study. Front Public Health. 2023. https:\/\/doi.org\/10.3389\/fpubh.2023.923319.","journal-title":"Front Public Health"},{"key":"11503_CR30","doi-asserted-by":"publisher","unstructured":"Ali AOA, Prins MH. Mobile health to improve adherence to tuberculosis treatment in khartoum state, sudan. J Public Health Afr. 2019;10. https:\/\/doi.org\/10.4081\/jphia.2019.1101","DOI":"10.4081\/jphia.2019.1101"},{"key":"11503_CR31","doi-asserted-by":"publisher","DOI":"10.1186\/s12889-018-5502-x","author":"G Bediang","year":"2018","unstructured":"Bediang G, Stoll B, Elia N, Abena JL, Geissbuhler A. SMS reminders to improve adherence and cure of tuberculosis patients in Cameroon (TB-SMS Cameroon): a randomised controlled trial. BMC Public Health. 2018. https:\/\/doi.org\/10.1186\/s12889-018-5502-x.","journal-title":"BMC Public Health"},{"key":"11503_CR32","doi-asserted-by":"publisher","first-page":"689","DOI":"10.7326\/M17-1150","volume":"167","author":"R Belknap","year":"2017","unstructured":"Belknap R, Holland D, Feng PJ, Millet JP, Cayla JA, Martinson NA, et al. Self-administered versus directly observed once-weekly isoniazid and rifapentine treatment of latent tuberculosis infection. Ann Intern Med. 2017;167:689\u201397. https:\/\/doi.org\/10.7326\/M17-1150.","journal-title":"Ann Intern Med"},{"key":"11503_CR33","doi-asserted-by":"publisher","unstructured":"Dewi FST, Sudiya S, Supriyati Supriyati, Utarini A. Preparing Short Message Service Reminders to Improve Treatment Adherence among Tuberculosis Patients in Sleman District, Indonesia. Indian J Community Med. 2019;44: 81\u201387. https:\/\/doi.org\/10.4103\/IJCM.IJCM_207_18","DOI":"10.4103\/IJCM.IJCM_207_18"},{"key":"11503_CR34","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.12659\/MSM.904957","volume":"23","author":"XH Fang","year":"2017","unstructured":"Fang XH, Guan SY, Tang L, Tao FB, Zou Z, Wang JX, et al. Effect of short message service on management of pulmonary tuberculosis patients in Anhui Province, China: a prospective, randomized, controlled study. Med Sci Monit. 2017;23:2465\u20139. https:\/\/doi.org\/10.12659\/MSM.904957.","journal-title":"Med Sci Monit"},{"key":"11503_CR35","unstructured":"Farooqi R, Ashraf S, Zaman M. THE ROLE OF MOBILE SMS-REMINDERS IN IMPROVING DRUGS COMPLIANCE IN PATIENTS RECEIVING ANTI-TB TREATMENT FROM DOTS PROGRAM. Journal of Postgraduate Medical Institute. 2017."},{"key":"11503_CR36","doi-asserted-by":"publisher","DOI":"10.1136\/bmjhci-2020-100268","author":"KD Gashu","year":"2021","unstructured":"Gashu KD, Gelaye KA, Lester R, Tilahun B. Effect of a phone reminder system on patient-centered tuberculosis treatment adherence among adults in northwest ethiopia: a randomised controlled trial. BMJ Health Care Inform. 2021. https:\/\/doi.org\/10.1136\/bmjhci-2020-100268.","journal-title":"BMJ Health Care Inform"},{"key":"11503_CR37","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.2147\/PPA.S135540","volume":"11","author":"SM Hermans","year":"2017","unstructured":"Hermans SM, Elbireer S, Tibakabikoba H, Hoefman BJ, Manabe YC. Text messaging to decrease tuberculosis treatment attrition in TB-HIV coinfection in Uganda. Patient Prefer Adherence. 2017;11:1479\u201387. https:\/\/doi.org\/10.2147\/PPA.S135540.","journal-title":"Patient Prefer Adherence"},{"key":"11503_CR38","doi-asserted-by":"publisher","first-page":"S37","DOI":"10.1097\/QAI.0000000000001202","volume":"74","author":"Y Hirsch-Moverman","year":"2017","unstructured":"Hirsch-Moverman Y, Daftary A, Yuengling KA, Saito S, Ntoane M, Frederix K, et al. Using mHealth for HIV\/TB treatment support in Lesotho: enhancing patient-provider communication in the START study. J Acquir Immune Defic Syndr. 2017;74:S37. https:\/\/doi.org\/10.1097\/QAI.0000000000001202.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"11503_CR39","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01488-2017","author":"JC Johnston","year":"2018","unstructured":"Johnston JC, van der Kop ML, Smillie K, Ogilvie G, Marra F, Sadatsafavi M, et al. The effect of text messaging on latent tuberculosis treatment adherence: a randomised controlled trial. Eur Respir J. 2018. https:\/\/doi.org\/10.1183\/13993003.01488-2017.","journal-title":"Eur Respir J"},{"key":"11503_CR40","doi-asserted-by":"publisher","unstructured":"Kibu OD, Siysi VV, Albert Legrand SE, Asangbeng Tanue E, Nsagha DS. Treatment Adherence among HIV and TB Patients Using Single and Double Way Mobile Phone Text Messages: A Randomized Controlled Trial. J Trop Med. 2022;2022. https:\/\/doi.org\/10.1155\/2022\/2980141","DOI":"10.1155\/2022\/2980141"},{"key":"11503_CR41","doi-asserted-by":"publisher","unstructured":"Kumboyono. Short message service as an alternative in the drug consumption evaluation of persons with tuberculosis in Malang, Indonesia. Japan Journal of Nursing Science. 2017;14: 112\u2013116. https:\/\/doi.org\/10.1111\/jjns.12140","DOI":"10.1111\/jjns.12140"},{"key":"11503_CR42","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2021-056496","author":"G Louwagie","year":"2022","unstructured":"Louwagie G, Kanaan M, Morojele NK, Van Zyl A, Moriarty AS, Li J, et al. Effect of a brief motivational interview and text message intervention targeting tobacco smoking, alcohol use and medication adherence to improve tuberculosis treatment outcomes in adult patients with tuberculosis: a multicentre, randomised controlled trial of the ProLife programme in South Africa. BMJ Open. 2022. https:\/\/doi.org\/10.1136\/bmjopen-2021-056496.","journal-title":"BMJ Open"},{"key":"11503_CR43","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0162944","author":"S Mohammed","year":"2016","unstructured":"Mohammed S, Glennerster R, Khan AJ. Impact of a daily SMS medication reminder system on tuberculosis treatment outcomes: a randomized controlled trial. PLoS ONE. 2016. https:\/\/doi.org\/10.1371\/journal.pone.0162944.","journal-title":"PLoS ONE"},{"key":"11503_CR44","unstructured":"Nguyen TS, Nguyen NT, Bao B, Byrkit R, Dao S. Mobile health and tuberculosis treatment adherence: a way forward? 45th Union World Conference on Lung Health. Barcelona, Spain: International Union Against Tuberculosis and Lung Disease (The Union); 2014. pp. S214\u2013215."},{"key":"11503_CR45","unstructured":"Owiti P, Szkwarko D, Diero L, Carter EJ, Gardner A. Mobile phone text mesaging reminders to aid adherence to tuberculosis care in Eldoret, Kenya. 43rd Union World Conference on Lung Health. Kuala Lumpur, Malaysia: International Union Against Tuberculosis and Lung Disease (The Union); 2012. pp. S200\u2013201."},{"key":"11503_CR46","unstructured":"Peng H, Xu WG, Lu WEI. Mobile phone text messaging forpromoting adherence to anti-tuberculosis treatment: a community-randomised trial in Jiangsu, China. 45th Union World Conference on Lung Health. Barcelona, Spain: International Union Against Tuberculosis and Lung Disease (The Union); 2014. pp. S213\u2013214."},{"key":"11503_CR47","doi-asserted-by":"publisher","DOI":"10.2196\/38247","author":"P Bachina","year":"2022","unstructured":"Bachina P, Lippincott CK, Perry A, Munk E, Maltas G, Bohr R, et al. Programmatic adoption and implementation of video-observed therapy in Minnesota: prospective observational cohort study. JMIR Form Res. 2022. https:\/\/doi.org\/10.2196\/38247.","journal-title":"JMIR Form Res"},{"key":"11503_CR48","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.44210","author":"J Burzynski","year":"2022","unstructured":"Burzynski J, Mangan JM, Lam CK, Macaraig M, Salerno MM, Decastro BR, et al. In-person vs electronic directly observed therapy for tuberculosis treatment adherence: a randomized noninferiority trial. JAMA Netw Open. 2022. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.44210.","journal-title":"JAMA Netw Open"},{"key":"11503_CR49","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1016\/j.jiph.2020.03.013","volume":"13","author":"SH Chen","year":"2020","unstructured":"Chen SH, Wang I, Hsu HL, Huang CC, Liu YJ, Putri DU, et al. Advantage in privacy protection by using synchronous video observed treatment enhances treatment adherence among patients with latent tuberculosis infection. J Infect Public Health. 2020;13:1354\u20139. https:\/\/doi.org\/10.1016\/j.jiph.2020.03.013.","journal-title":"J Infect Public Health"},{"key":"11503_CR50","doi-asserted-by":"publisher","first-page":"588","DOI":"10.5588\/ijtld.15.0738","volume":"20","author":"C Chuck","year":"2016","unstructured":"Chuck C, Robinson E, Macaraig M, Alexander M, Burzynski J. Enhancing management of tuberculosis treatment with video directly observed therapy in New York City. Int J Tuberc Lung Dis. 2016;20:588\u201393. https:\/\/doi.org\/10.5588\/ijtld.15.0738.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11503_CR51","doi-asserted-by":"publisher","first-page":"17S","DOI":"10.3855\/jidc.14601","volume":"15","author":"S Doltu","year":"2021","unstructured":"Doltu S, Ciobanu A, Sereda Y, Persian R, Ravenscroft L, Kasyan L, et al. Short and long-term outcomes of video observed treatment in tuberculosis patients, the Republic of Moldova. J Infect Dev Ctries. 2021;15:17S-24S. https:\/\/doi.org\/10.3855\/jidc.14601.","journal-title":"J Infect Dev Ctries"},{"key":"11503_CR52","doi-asserted-by":"publisher","first-page":"1806","DOI":"10.3201\/eid2410.180459","volume":"24","author":"RS Garfein","year":"2018","unstructured":"Garfein RS, Liu L, Cuevas-Mota J, Collins K, Mu\u00f1oz F, Catanzaro DG, et al. Tuberculosis treatment monitoring by video directly observed therapy in 5 health districts, California, USA. Emerg Infect Dis. 2018;24:1806\u201315. https:\/\/doi.org\/10.3201\/eid2410.180459.","journal-title":"Emerg Infect Dis"},{"key":"11503_CR53","doi-asserted-by":"publisher","DOI":"10.2196\/17658","author":"X Guo","year":"2020","unstructured":"Guo X, Yang Y, Takiff HE, Zhu M, Ma J, Zhong T, et al. A comprehensive app that improves tuberculosis treatment management through video-observed therapy: usability study. JMIR Mhealth Uhealth. 2020. https:\/\/doi.org\/10.2196\/17658.","journal-title":"JMIR Mhealth Uhealth"},{"key":"11503_CR54","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1089\/tmj.2019.0190","volume":"26","author":"P Guo","year":"2020","unstructured":"Guo P, Qiao W, Sun Y, Liu F, Wang C. Telemedicine technologies and tuberculosis management: a randomized controlled trial. Telemed e-Health. 2020;26:1150\u20136. https:\/\/doi.org\/10.1089\/tmj.2019.0190.","journal-title":"Telemed e-Health"},{"key":"11503_CR55","doi-asserted-by":"publisher","unstructured":"Lam CK, Pilote KMG, Haque A, Burzynski J, Chuck C, Macaraig M. Using video technology to increase treatment completion for patients with latent tuberculosis infection on 3-month isoniazid and rifapentine: An implementation study. J Med Internet Res. 2018;20. https:\/\/doi.org\/10.2196\/jmir.9825","DOI":"10.2196\/jmir.9825"},{"key":"11503_CR56","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07787-4","author":"CK Lippincott","year":"2022","unstructured":"Lippincott CK, Perry A, Munk E, Maltas G, Shah M. Tuberculosis treatment adherence in the era of COVID-19. BMC Infect Dis. 2022. https:\/\/doi.org\/10.1186\/s12879-022-07787-4.","journal-title":"BMC Infect Dis"},{"key":"11503_CR57","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5588\/ijtld.21.0170","volume":"25","author":"A Perry","year":"2021","unstructured":"Perry A, Chitnis A, Chin A, Hoffmann C, Chang L, Robinson M, et al. Real-world implementation of video-observed therapy in an urban TB program in the United States. Int J Tuberc Lung Dis. 2021;25:655\u201361. https:\/\/doi.org\/10.5588\/ijtld.21.0170.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11503_CR58","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.00493-2020","author":"L Ravenscroft","year":"2020","unstructured":"Ravenscroft L, Kettle S, Persian R, Ruda S, Severin L, Doltu S, et al. Video-observed therapy and medication adherence for tuberculosis patients: randomised controlled trial in Moldova. Eur Respir J. 2020. https:\/\/doi.org\/10.1183\/13993003.00493-2020.","journal-title":"Eur Respir J"},{"key":"11503_CR59","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0254950","author":"J Salcedo","year":"2021","unstructured":"Salcedo J, Rosales M, Kim JS, Nuno D, Suen S, Chang AH. Cost-effectiveness of artificial intelligence monitoring for active tuberculosis treatment: a modeling study. PLoS ONE. 2021. https:\/\/doi.org\/10.1371\/journal.pone.0254950.","journal-title":"PLoS ONE"},{"key":"11503_CR60","doi-asserted-by":"publisher","first-page":"833","DOI":"10.5588\/ijtld.22.0594","volume":"27","author":"MM Salerno","year":"2023","unstructured":"Salerno MM, Burzynski J, Mangan JM, Hill A, deCastro BR, Goswami ND, et al. Adverse events among persons with TB using in-person vs. electronic directly observed therapy. Int J Tuberc Lung Dis. 2023;27:833\u201340. https:\/\/doi.org\/10.5588\/ijtld.22.0594.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11503_CR61","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1016\/S0140-6736(18)32993-3","volume":"393","author":"A Story","year":"2019","unstructured":"Story A, Aldridge RW, Smith CM, Garber E, Hall J, Ferenando G, et al. Smartphone-enabled video-observed versus directly observed treatment for tuberculosis: a multicentre, analyst-blinded, randomised, controlled superiority trial. Lancet. 2019;393:1216\u201324. https:\/\/doi.org\/10.1016\/S0140-6736(18)32993-3.","journal-title":"Lancet"},{"key":"11503_CR62","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0050155","author":"VA Wade","year":"2012","unstructured":"Wade VA, Karnon J, Eliott JA, Hiller JE. Home videophones improve direct observation in tuberculosis treatment: a mixed methods evaluation. PLoS ONE. 2012. https:\/\/doi.org\/10.1371\/journal.pone.0050155.","journal-title":"PLoS ONE"},{"key":"11503_CR63","unstructured":"Yu MC, Feng WH, Shia TF, Hsu KM, Lin H C. Application of mobile videophone in the DOTS-Plus program of northern Taiwan. 44th Union World Conference on Lung Health. Paris, France: International Union Against Tuberculosis and Lung Disease (The Union); 2013. pp. S559\u2013560."},{"key":"11503_CR64","doi-asserted-by":"publisher","first-page":"44","DOI":"10.5588\/ijtld.21.0373","volume":"26","author":"J Acosta","year":"2022","unstructured":"Acosta J, Flores P, Alarc\u00f3n M, Grande-Ortiz M, Moreno-Exebio L, Puyen ZM. A randomised controlled trial to evaluate a medication monitoring system for TB treatment. Int J Tuberc Lung Dis. 2022;26:44\u20139. https:\/\/doi.org\/10.5588\/ijtld.21.0373.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11503_CR65","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1089\/tmj.2011.0143","volume":"18","author":"S Broomhead","year":"2012","unstructured":"Broomhead S, Mars M. Retrospective return on investment analysis of an electronic treatment adherence device piloted in the Northern Cape Province. Telemedicine and e-Health. 2012;18:24\u201331. https:\/\/doi.org\/10.1089\/tmj.2011.0143.","journal-title":"Telemedicine and e-Health"},{"key":"11503_CR66","unstructured":"Charalambous S, Jennings L, Rabothata I, Mukora R, Xaba N, Mchunu L, et al. TB treatment adherence amongst drug-susceptible TB persons using medication monitor and differentiated care approach versus standard of care in South Africa. 53rd Union World Conference on Lung Health. Virtual: International Union Against Tuberculosis and Lung Disease (The Union); 2022. p. S302."},{"key":"11503_CR67","doi-asserted-by":"publisher","first-page":"7497","DOI":"10.2147\/IDR.S438962","volume":"16","author":"G Guo","year":"2023","unstructured":"Guo G, Zheng Y, Ma X, Sun L, Wushouer Q, Jia B, et al. eDOTS: improving the treatment of pulmonary tuberculosis in Xinjiang, China. Infect Drug Resist. 2023;16:7497\u2013505. https:\/\/doi.org\/10.2147\/IDR.S438962.","journal-title":"Infect Drug Resist"},{"key":"11503_CR68","unstructured":"Kurada J, Chittiboyina S, Devi C, Adepu R, Ramachandran R, Rao R, et al. Treatment adherence by real-time medication event reminder monitor device in Hyderabad, Telangana State: a cohort study. 50th Union World Conference on Lung Health. Hyderabad, India: International Union Against Tuberculosis and Lung Disease (The Union); 2019. pp. S234\u2013235."},{"key":"11503_CR69","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00068-2","volume":"11","author":"X Liu","year":"2023","unstructured":"Liu X, Thompson J, Dong H, Sweeney S, Li X, Yuan Y, et al. Digital adherence technologies to improve tuberculosis treatment outcomes in China: a cluster-randomised superiority trial. Lancet Glob Health. 2023;11: e693\u2013e703. https:\/\/doi.org\/10.1016\/S2214-109X(23)00068-2.","journal-title":"Lancet Glob Health"},{"key":"11503_CR70","doi-asserted-by":"publisher","DOI":"10.1186\/s12916-022-02521-y","author":"T Manyazewal","year":"2022","unstructured":"Manyazewal T, Woldeamanuel Y, Holland DP, Fekadu A, Marconi VC. Effectiveness of a digital medication event reminder and monitor device for patients with tuberculosis (SELFTB): a multicenter randomized controlled trial. BMC Med. 2022. https:\/\/doi.org\/10.1186\/s12916-022-02521-y.","journal-title":"BMC Med"},{"key":"11503_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101820","author":"T Manyazewal","year":"2023","unstructured":"Manyazewal T, Woldeamanuel Y, Getinet T, Hoover A, Bobosha K, Fuad O, et al. Patient-reported usability and satisfaction with electronic medication event reminder and monitor device for tuberculosis: a multicentre, randomised controlled trial. EClinicalMedicine. 2023. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101820.","journal-title":"EClinicalMedicine"},{"key":"11503_CR72","doi-asserted-by":"publisher","first-page":"E2230509","DOI":"10.1001\/jamanetworkopen.2022.30509","volume":"5","author":"T Manyazewal","year":"2022","unstructured":"Manyazewal T, Woldeamanuel Y, Fekadu A, Holland DP, Marconi VC. Effect of digital medication event reminder and monitor-observed therapy vs standard directly observed therapy on health-related quality of life and catastrophic costs in patients with tuberculosis: a secondary analysis of a randomized clinical trial. JAMA Netw Open. 2022;5:E2230509. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.30509.","journal-title":"JAMA Netw Open"},{"key":"11503_CR73","unstructured":"Moulding TS, Caymittes M, Moulding T. Managing medication compliance of tuberculosis patients in Haiti with medication monitors Petion-Ville, Haiti. INT J TUBERC LUNG DIS. 2002."},{"key":"11503_CR74","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph16030412","author":"S Park","year":"2019","unstructured":"Park S, Sentissi I, Gil SJ, Park WS, Oh BK, Son AR, et al. Medication event monitoring system for infectious tuberculosis treatment in Morocco: a retrospective cohort study. Int J Environ Res Public Health. 2019. https:\/\/doi.org\/10.3390\/ijerph16030412.","journal-title":"Int J Environ Res Public Health"},{"key":"11503_CR75","unstructured":"Pima FM, Ngowi KM, Maro R, de-Boer MS, Msangi S, Mtesha B, et al. Effectiveness of evriMED in ensuring TB treatment adherence among TB patients in the Kilimanjaro Region: a cluster-randomised controlled two-armed trial. 52nd Union World Conference on Lung Health. Virtual: International Union Against Tuberculosis and Lung Disease (The Union); 2021. p. S131."},{"key":"11503_CR76","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1080\/23744235.2019.1688862","volume":"52","author":"R Ratchakit-Nedsuwan","year":"2020","unstructured":"Ratchakit-Nedsuwan R, Nedsuwan S, Sawadna V, Chaiyasirinroje B, Bupachat S, Ngamwithayapong-Yanai J, et al. Ensuring tuberculosis treatment adherence with a mobile-based CARE-call system in Thailand: a pilot study. Infect Dis. 2020;52:121\u20139. https:\/\/doi.org\/10.1080\/23744235.2019.1688862.","journal-title":"Infect Dis"},{"key":"11503_CR77","doi-asserted-by":"publisher","unstructured":"Saha S, Saxena D, Raval D, Halkarni N, Doshi R, Joshi M, et al. Tuberculosis Monitoring Encouragement Adherence Drive (TMEAD): Toward improving the adherence of the patients with drug-sensitive tuberculosis in Nashik, Maharashtra. Front Public Health. 2022;10. https:\/\/doi.org\/10.3389\/FPUBH.2022.1021427\/FULL","DOI":"10.3389\/FPUBH.2022.1021427\/FULL"},{"key":"11503_CR78","doi-asserted-by":"publisher","first-page":"322","DOI":"10.5588\/ijtld.22.0500","volume":"27","author":"K Velen","year":"2023","unstructured":"Velen K, Nguyen TA, Pham CD, Le HT, Nguyen HB, Dao BT, et al. The effect of medication event reminder monitoring on treatment adherence of TB patients. Int J Tuberc Lung Dis. 2023;27:322\u20138. https:\/\/doi.org\/10.5588\/ijtld.22.0500.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11503_CR79","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0242112","author":"N Wang","year":"2020","unstructured":"Wang N, Shewade HD, Thekkur P, Zhang H, Yuan Y, Wang X, et al. Do electronic medication monitors improve tuberculosis treatment outcomes? Programmatic experience from China. PLoS ONE. 2020. https:\/\/doi.org\/10.1371\/journal.pone.0242112.","journal-title":"PLoS ONE"},{"key":"11503_CR80","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(23)02270-5","volume":"403","author":"X Wei","year":"2024","unstructured":"Wei X, Hicks JP, Zhang Z, Haldane V, Pasang P, Li L, et al. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial. Lancet. 2024;403:913\u201323. https:\/\/doi.org\/10.1016\/S0140-6736(23)02270-5.","journal-title":"Lancet"},{"key":"11503_CR81","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1097\/QAI.0000000000001025","volume":"73","author":"IV Bassett","year":"2016","unstructured":"Bassett IV, Coleman SM, Giddy J, Bogart LM, Chaisson CE, Ross D, et al. Sizanani: A Randomized Trial of Health System Navigators to Improve Linkage to HIV and TB Care in South Africa. J Acquir Immune Defic Syndr. 2016;73:154. https:\/\/doi.org\/10.1097\/QAI.0000000000001025.","journal-title":"J Acquir Immune Defic Syndr"},{"key":"11503_CR82","unstructured":"Hope M, Nsubuga T, Zawedde-Muyanja S, Etwom A, Obaikol R, Parkes-Ratanshi R, et al. Impact of a digital adherence support intervention on TB treatment outcomes in a nomadic population: a case study of five facilities in Karamoja subregion, Uganda. 53rd Union World Conference on Lung Health. Virtual: International Union Against Tuberculosis and Lung Disease (The Union); 2022. p. S120."},{"key":"11503_CR83","unstructured":"Hope M, Sekaggya-Wiltshire C, Nanyonjo M, Kiragga A, Lamorde M, Oseku E, et al. Impact of a mobile phone-based interactive voice response software on tuberculosis treatment outcomes at public facilities in Uganda. 53rd Union World Conference on Lung Health. Virtual: International Union Against Tuberculosis and Lung Disease (The Union); 2022. pp. S209\u2013210."},{"key":"11503_CR84","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-1141-y","author":"V Khachadourian","year":"2020","unstructured":"Khachadourian V, Truzyan N, Harutyunyan A, Petrosyan V, Davtyan H, Davtyan K, et al. People-centred care versus clinic-based DOT for continuation phase TB treatment in Armenia: a cluster randomized trial. BMC Pulm Med. 2020. https:\/\/doi.org\/10.1186\/s12890-020-1141-y.","journal-title":"BMC Pulm Med"},{"key":"11503_CR85","doi-asserted-by":"publisher","first-page":"34","DOI":"10.4103\/ijph.IJPH_879_20","volume":"65","author":"S Santra","year":"2021","unstructured":"Santra S, Garg S, Basu S, Sharma N, Singh MM, Khanna A. The effect of a mHealth intervention on anti-tuberculosis medication adherence in Delhi, India: a quasi-experimental study. Indian J Public Health. 2021;65:34\u20138. https:\/\/doi.org\/10.4103\/ijph.IJPH_879_20.","journal-title":"Indian J Public Health"},{"key":"11503_CR86","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.1003628","author":"A Cattamanchi","year":"2021","unstructured":"Cattamanchi A, Crowder R, Kityamuwesi A, Kiwanuka N, Lamunu M, Namale C, et al. Digital adherence technology for tuberculosis treatment supervision: a stepped-wedge cluster-randomized trial in Uganda. PLoS Med. 2021. https:\/\/doi.org\/10.1371\/journal.pmed.1003628.","journal-title":"PLoS Med"},{"key":"11503_CR87","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-023-08418-2","author":"AZ Chen","year":"2023","unstructured":"Chen AZ, Kumar R, Baria RK, Shridhar PK, Subbaraman R, Thies W. Impact of the 99DOTS digital adherence technology on tuberculosis treatment outcomes in North India: a pre-post study. BMC Infect Dis. 2023. https:\/\/doi.org\/10.1186\/s12879-023-08418-2.","journal-title":"BMC Infect Dis"},{"key":"11503_CR88","doi-asserted-by":"publisher","unstructured":"Crowder R, Nakasendwa S, Kityamuwesi A, Musoke M, Nannozi J, Waswa J, et al. Implementation of enhanced 99DOTS for TB treatment supervision in Uganda: An interrupted time series analysis. medRxiv. 2024; 2024.01.22.24300949. https:\/\/doi.org\/10.1101\/2024.01.22.24300949","DOI":"10.1101\/2024.01.22.24300949"},{"key":"11503_CR89","doi-asserted-by":"publisher","unstructured":"Thekkur P, Kumar ANV, Chinnakali P, Selvaraju S, Bairy R, Singh AR, et al. Outcomes and implementation challenges of using daily treatment regimens with an innovative adherence support tool among HIV-infected tuberculosis patients in Karnataka, India: a mixed-methods study. Glob Health Action. 2019;12. https:\/\/doi.org\/10.1080\/16549716.2019.1568826","DOI":"10.1080\/16549716.2019.1568826"},{"key":"11503_CR90","unstructured":"Wambi P, Crowder R, Sanyu A, Nannozi J, Musoke M, Wobudeya E, et al. The role of 99DOTS digital adhenrance technology to support tuberculosis treatment adherance among adolescents. 53rd Union World Conference on Lung Health. Virtual: International Union Against Tuberculosis and Lung Disease (The Union); 2022. pp. S305\u2013306."},{"key":"11503_CR91","doi-asserted-by":"publisher","unstructured":"Haslinda Noor I. JMH. EFFECTIVENESS OF HEALTH EDUCATION MODULE DELIVERED THROUGH WHATSAPP TO ENHANCE TREATMENT ADHERENCE AND SUCCESSFUL OUTCOME OF TUBERCULOSIS IN SEREMBAN DISTRICT, NEGERI SEMBILAN, MALAYSIA. International Journal of Public Health and Clinical Sciences. 2019;6. https:\/\/doi.org\/10.32827\/ijphcs.6.4.145","DOI":"10.32827\/ijphcs.6.4.145"},{"issue":"3","key":"11503_CR92","doi-asserted-by":"publisher","first-page":"46","DOI":"10.29413\/ABS.2020-5.3.7","volume":"5","author":"SN Zhdanova","year":"2020","unstructured":"Zhdanova SN, Ogarkov OB, Heysell SK. Mobile health intervention for outpatient treatment of tuberculosis and HIV infection. Acta Biomedica Scientifica (East Siberian Biomedical Journal). 2020;5(3):46\u201353. https:\/\/doi.org\/10.29413\/ABS.2020-5.3.7.","journal-title":"Acta Biomedica Scientifica (East Siberian Biomedical Journal)"},{"key":"11503_CR93","doi-asserted-by":"crossref","unstructured":"Zhang M, Wang G, Najmi H, Yaqoob A, Li T, Xia Y, et al. OPEN ACCESS EDITED BY Digitizing tuberculosis treatment monitoring in Wuhan city, China, Impact on medication adherence. 2023.","DOI":"10.3389\/fpubh.2023.1033532"},{"key":"11503_CR94","unstructured":"Zhou X, Zuo T, Zhao X, Cheng T, Zhao J. Effect of mobile app-based nursing health education on patients with pulmonary multidrug-resistant tuberculosis. 49th Union World Conference on Lung Health. The Hague, The Netherlands: International Union Against Tuberculosis and Lung Disease (The Union); 2018. p. S288."},{"key":"11503_CR95","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgph.0001813","volume":"3","author":"A Musiimenta","year":"2023","unstructured":"Musiimenta A, Tumuhimbise W, Atukunda EC, Mugaba AT, Musinguzi N, Muzoora C, et al. The feasibility, acceptability, and preliminary impact of real-time monitors and SMS on tuberculosis medication adherence in southwestern Uganda: findings from a mixed methods pilot randomized controlled trial. PLoS Glob Public Health. 2023;3: e0001813. https:\/\/doi.org\/10.1371\/journal.pgph.0001813.","journal-title":"PLoS Glob Public Health"},{"key":"11503_CR96","doi-asserted-by":"publisher","first-page":"432","DOI":"10.5588\/IJTLD.23.0027","volume":"27","author":"C Oeser","year":"2023","unstructured":"Oeser C, Rangaka MX, Abubakar I. Digital approaches to reducing TB treatment loss to follow-up. Int J Tuberc Lung Dis. 2023;27:432\u20137. https:\/\/doi.org\/10.5588\/IJTLD.23.0027.","journal-title":"Int J Tuberc Lung Dis"},{"key":"11503_CR97","doi-asserted-by":"publisher","DOI":"10.1136\/bmjgh-2024-015654","author":"C Kafie","year":"2024","unstructured":"Kafie C, Mohamed MS, Zary M, Chilala CI, Bahukudumbi S, Gore G, et al. Cost and cost-effectiveness of digital technologies for support of tuberculosis treatment adherence: a systematic review. BMJ Glob Health. 2024. https:\/\/doi.org\/10.1136\/bmjgh-2024-015654.","journal-title":"BMJ Glob Health"},{"key":"11503_CR98","doi-asserted-by":"publisher","unstructured":"Chilala CI, Foster N, Bahukudumbi S, Mohamed MS, Zary M, Kafie C, et al. Implementation outcomes of tuberculosis digital adherence technologies: a scoping review using the RE-AIM framework. BMJ Global Health. 2025;10:e016535. https:\/\/doi.org\/10.1136\/bmjgh-2024-016535","DOI":"10.1136\/bmjgh-2024-016535"},{"key":"11503_CR99","doi-asserted-by":"publisher","unstructured":"Subbaraman R, Thomas BE, Kumar JV, Lubeck-Schricker M, Khandewale A, Thies W, et al. Measuring Tuberculosis Medication Adherence: A Comparison of Multiple Approaches in Relation to Urine Isoniazid Metabolite Testing Within a Cohort Study in India. Open Forum Infect Dis. 2021;8. https:\/\/doi.org\/10.1093\/OFID\/OFAB532","DOI":"10.1093\/OFID\/OFAB532"},{"key":"11503_CR100","doi-asserted-by":"publisher","unstructured":"N Bionghi A Daftary B Maharaj Z Msibi KR Amico G Friedland et al 2018 Pilot evaluation of a second-generation electronic pill box for adherence to Bedaquiline and antiretroviral therapy in drug-resistant TB\/HIV co-infected patients in KwaZulu-Natal, South Africa BMC Infect Dis 1 https:\/\/doi.org\/10.1186\/s12879-018-3080-2","DOI":"10.1186\/s12879-018-3080-2"},{"key":"11503_CR101","doi-asserted-by":"publisher","first-page":"632","DOI":"10.2471\/BLT.11.086462","volume":"89","author":"J Van Den Boogaard","year":"2011","unstructured":"Van Den Boogaard J, Lyimo RA, Boeree MJ, Kibiki GS, Aarnoutse RE. Electronic monitoring of treatment adherence and validation of alternative adherence measures in tuberculosis patients: a pilot study. Bull World Health Organ. 2011;89:632\u20139. https:\/\/doi.org\/10.2471\/BLT.11.086462.","journal-title":"Bull World Health Organ"},{"key":"11503_CR102","doi-asserted-by":"publisher","unstructured":"Zary M, Mohamed MS, Kafie C, Chilala CI, Bahukudumbi S, Foster N, et al. The performance of digital technologies for measuring tuberculosis medication adherence: a systematic review. BMJ Global Health. 2024;9:e015633. https:\/\/doi.org\/10.1136\/bmjgh-2024-015633","DOI":"10.1136\/bmjgh-2024-015633"},{"key":"11503_CR103","doi-asserted-by":"publisher","unstructured":"Bahukudumbi S, Chilala CI, Foster N, Patel B, Mohamed MS, Zary M, et al. Contextual factors influencing implementation of tuberculosis digital adherence technologies: a scoping review guided by the RE-AIM framework. BMJ Global Health. 2025;10:e016608. https:\/\/doi.org\/10.1136\/bmjgh-2024-016608","DOI":"10.1136\/bmjgh-2024-016608"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11503-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11503-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11503-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T12:15:40Z","timestamp":1781612140000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11503-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,14]]},"references-count":103,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11503"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11503-3","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,14]]},"assertion":[{"value":"27 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Dr. Kevin Schwartzman reports research funding from the Canadian Institutes of Health Research. He has also served as chair of the Data Safety and Monitoring Board for a COVID-19 therapeutic investigated by Laurent Pharmaceuticals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1314"}}